AnaptysBio Inc (ANAB)vsRegeneron Pharmaceuticals Inc (REGN)
ANAB
AnaptysBio Inc
$50.37
-2.52%
HEALTHCARE · Cap: $1.56B
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.46%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 6320% more annual revenue ($14.92B vs $232.39M). REGN leads profitability with a 29.6% profit margin vs -11.5%. REGN earns a higher WallStSmart Score of 64/100 (C+).
ANAB
Avoid21
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+85.7%
Fair Value
$385.19
Current Price
$50.37
$334.82 discount
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 114.5x book value
ROE of -210.1% — below average capital efficiency
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ANAB
ANAB has a balanced fundamental profile.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : ANAB
The primary concerns for ANAB are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 21.76 is elevated, increasing financial risk.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ANAB profiles as a turnaround stock while REGN is a growth play — different risk/reward profiles.
ANAB carries more volatility with a beta of 0.48 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 21/100), backed by strong 29.6% margins and 19.0% revenue growth. ANAB offers better value entry with a 85.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AnaptysBio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?